Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators. Le Tourneau C, et al. Among authors: gentien d. Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3. Lancet Oncol. 2015. PMID: 26342236 Clinical Trial.
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F. de Cremoux P, et al. Among authors: gentien d. BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215. BMC Cancer. 2011. PMID: 21631949 Free PMC article. Clinical Trial.
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Among authors: gentien d. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
Molecular profiling of patient-derived breast cancer xenografts.
Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Reyal F, et al. Among authors: gentien d. Breast Cancer Res. 2012 Jan 16;14(1):R11. doi: 10.1186/bcr3095. Breast Cancer Res. 2012. PMID: 22247967 Free PMC article.
Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.
Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L, Mariani P, Lantz O, Stern MH. Madic J, et al. Among authors: gentien d. Clin Cancer Res. 2012 Jul 15;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645051
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T. Maire V, et al. Among authors: gentien d. Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9. Cancer Res. 2013. PMID: 23144294
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
Le Tourneau C, Kamal M, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X. Le Tourneau C, et al. Among authors: gentien d. Target Oncol. 2012 Dec;7(4):253-65. doi: 10.1007/s11523-012-0237-6. Epub 2012 Nov 17. Target Oncol. 2012. PMID: 23161020 Review.
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T. Maire V, et al. Among authors: gentien d. PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013. PLoS One. 2013. PMID: 23700430 Free PMC article.
96 results